Lupin, Pred Forte
Lupin launches first generic of Pred Forte in US with 180-day exclusivity
Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic equivalent of Pred Forte Ophthalmic Suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Lupin Launches Generic Eye Treatment in US | 180-Day Exclusivity
Lupin has launched a generic ophthalmic solution in the US, Pred Forte (Prednisolone Acetate) Ophthalmic Suspension USP, 1 per cent, with 180-day exclusivity. The drug is indicated for treating steroid-responsive inflammation of the eye.
A media report said that the US Center for Medicare and Medicaid released a preliminary list of 101 generic drugs.
Lupin share price slipped in trade after the company announced that United States Food and Drug Administration (USFDA) has ...
Lupin launches Aptivate Achi Bhookh Fest in Mumbai and suburbs: Our Bureau, Mumbai Monday, October 14, 2024, 15:30 Hrs [IST] LupinLife, the consumer healthcare division of global ...
Axis Securities has recommended seven midcap and smallcap stocks to buy in October and expects an upside potential of up to ...
Usage of generic medicines has been increased as they became boon to the poor and middle-class people because they are ...
Lupin's subsidiary, Pharma Dynamics, acquires 9 brands from MNI in South Africa, expanding its footprint in complementary and ...
Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada DENVER, CO / ACCESSWIRE / ...
Lupin Ltd.'s South African subsidiary acquires nine brands from MNI, expanding its portfolio in the healthcare sector.
This acquisition will enable Lupin gain access to MNI’s wide portfolio of nine brands, that are marketed as branded products in the South African retail sector, the company stated.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback